Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.61 |
| ▸ | CCR3 | P51677 | 20/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161536 | 0.91 | CCR3 (0.58) | HRH1CCR3KCNH2 | |
| SCHEMBL180150 | 0.85 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL180455 | 0.84 | HRH1 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL5194236 | 0.82 | HRH1 (0.67) | HRH1CCR3KCNH2 | |
| SCHEMBL5192090 | 0.81 | HRH1 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL180300 | 0.81 | HRH1 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL5192348 | 0.81 | HRH1 (0.74) | HRH1CCR3KCNH2 | |
| SCHEMBL5189712 | 0.81 | HRH1 (0.58) | HRH1CCR3KCNH2 | |
| SCHEMBL5192338 | 0.80 | HRH1 (0.62) | HRH1CCR3KCNH2 | |
| SCHEMBL5006426 | 0.80 | HRH1 (0.79) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | US | disclosed |
| EP-1620400-B1 | piperidinylmethylpiperidine derivatives and their use as chemokine modulators | ASTRAZENECA AB (SE) | 2012-12-05 | — | — | EP | disclosed |
| US-8314127-B2 | Piperidine derivatives | ASTRAZENECA AB (SE) | 2012-11-20 | — | — | US | disclosed |
| EP-1912941-B1 | PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-14 | — | — | EP | disclosed |
| EP-2402316-A1 | Piperidine derivatives | AstraZeneca AB (Publ) (SE) | 2012-01-04 | — | — | EP | disclosed |
| US-20080207688-A1 | Novel Piperidine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1816123-A1 | Intermediates for the production of pharmaceutically active compounds | AstraZeneca AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1546130-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207688-A1 | Novel Piperidine Derivatives | CCR3, CCR1, CCR4 | HRH1 276/4885CCR3 1/4885KCNH2 4090/4885 |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | CCR3, CCR1, CCR4 | HRH1 276/4885CCR3 1/4885KCNH2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.